Open AccessStreptozotocin - an antibiotic used to induce diabetes on experimental animals
Author(s) -
Dagna Siedlecka,
Wojciech Micał,
Ewa Krzewicka-Romaniuk
Publication year - 2020
Publication title -
journal of education, health and sport
Language(s) - English
Resource type - Journals
ISSN - 2391-8306
DOI - 10.12775/jehs.2020.10.09.110
Subject(s) - streptozotocin , insulitis , diabetes mellitus , pancreas , antibiotics , medicine , molecular medicine , necrosis , pharmacology , endocrinology , biology , cancer , microbiology and biotechnology , islet , cell cycle
Streptozotocin (STZ) is a cytostatic antibiotic produced by Streptomyces achromogenes. It is an inhibitor of DNA replication showing a special affinity for pancreatic β-cells DNA. It is used in medicine as an antineoplastic agent (indicated in the treatment of malignant neoplasms of pancreas) and in scientific research to induce hyperglycemia, insulitis, diabetes mellitus (DM), Alzheimer’s disease on experimental animals. Insulinopenia syndrome is called ‘streptozotocin diabetes’, caused by necrosis of the pancreatic β-cells. STZ induced DM offers a very cost-effective and expeditious technique in medical research.